These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 31629422)

  • 21. Germline genetic testing for inherited prostate cancer in practice: Implications for genetic testing, precision therapy, and cascade testing.
    Giri VN; Hegarty SE; Hyatt C; O'Leary E; Garcia J; Knudsen KE; Kelly WK; Gomella LG
    Prostate; 2019 Mar; 79(4):333-339. PubMed ID: 30450585
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Germline Mutations in ATM and BRCA1/2 Are Associated with Grade Reclassification in Men on Active Surveillance for Prostate Cancer.
    Carter HB; Helfand B; Mamawala M; Wu Y; Landis P; Yu H; Wiley K; Na R; Shi Z; Petkewicz J; Shah S; Fantus RJ; Novakovic K; Brendler CB; Zheng SL; Isaacs WB; Xu J
    Eur Urol; 2019 May; 75(5):743-749. PubMed ID: 30309687
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Germline genetic variants in men with prostate cancer and one or more additional cancers.
    Pilié PG; Johnson AM; Hanson KL; Dayno ME; Kapron AL; Stoffel EM; Cooney KA
    Cancer; 2017 Oct; 123(20):3925-3932. PubMed ID: 28657667
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A cohort analysis of men with a family history of BRCA1/2 and Lynch mutations for prostate cancer.
    Kerr L; Rewhorn MJ; Longmuir M; Fraser S; Walsh S; Andrew N; Leung HY
    BMC Cancer; 2016 Jul; 16():529. PubMed ID: 27456091
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017.
    Giri VN; Knudsen KE; Kelly WK; Abida W; Andriole GL; Bangma CH; Bekelman JE; Benson MC; Blanco A; Burnett A; Catalona WJ; Cooney KA; Cooperberg M; Crawford DE; Den RB; Dicker AP; Eggener S; Fleshner N; Freedman ML; Hamdy FC; Hoffman-Censits J; Hurwitz MD; Hyatt C; Isaacs WB; Kane CJ; Kantoff P; Karnes RJ; Karsh LI; Klein EA; Lin DW; Loughlin KR; Lu-Yao G; Malkowicz SB; Mann MJ; Mark JR; McCue PA; Miner MM; Morgan T; Moul JW; Myers RE; Nielsen SM; Obeid E; Pavlovich CP; Peiper SC; Penson DF; Petrylak D; Pettaway CA; Pilarski R; Pinto PA; Poage W; Raj GV; Rebbeck TR; Robson ME; Rosenberg MT; Sandler H; Sartor O; Schaeffer E; Schwartz GF; Shahin MS; Shore ND; Shuch B; Soule HR; Tomlins SA; Trabulsi EJ; Uzzo R; Vander Griend DJ; Walsh PC; Weil CJ; Wender R; Gomella LG
    J Clin Oncol; 2018 Feb; 36(4):414-424. PubMed ID: 29236593
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Germline Testing for Prostate Cancer Prognosis: Implications for Active Surveillance.
    Helfand BT; Xu J
    Urol Clin North Am; 2021 Aug; 48(3):401-409. PubMed ID: 34210494
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Germline testing for patients with metastatic and localized high-risk prostate cancer: Towards a widespread use?].
    Marchand-Créty C
    Bull Cancer; 2021 Nov; 108(11):994-998. PubMed ID: 34656301
    [No Abstract]   [Full Text] [Related]  

  • 28. Hereditary Prostate Cancer: Genes Related, Target Therapy and Prevention.
    Vietri MT; D'Elia G; Caliendo G; Resse M; Casamassimi A; Passariello L; Albanese L; Cioffi M; Molinari AM
    Int J Mol Sci; 2021 Apr; 22(7):. PubMed ID: 33916521
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Germline and somatic mutations in prostate cancer: Implications for treatment.
    Chalker C; Chun B; Sokolova AO
    Curr Probl Cancer; 2024 Jun; 50():101101. PubMed ID: 38718711
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PROREPAIR-B: A Prospective Cohort Study of the Impact of Germline DNA Repair Mutations on the Outcomes of Patients With Metastatic Castration-Resistant Prostate Cancer.
    Castro E; Romero-Laorden N; Del Pozo A; Lozano R; Medina A; Puente J; Piulats JM; Lorente D; Saez MI; Morales-Barrera R; Gonzalez-Billalabeitia E; Cendón Y; García-Carbonero I; Borrega P; Mendez Vidal MJ; Montesa A; Nombela P; Fernández-Parra E; Gonzalez Del Alba A; Villa-Guzmán JC; Ibáñez K; Rodriguez-Vida A; Magraner-Pardo L; Perez-Valderrama B; Vallespín E; Gallardo E; Vazquez S; Pritchard CC; Lapunzina P; Olmos D
    J Clin Oncol; 2019 Feb; 37(6):490-503. PubMed ID: 30625039
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Founder mutations in BRCA1/2 are not frequent in Canadian Ashkenazi Jewish men with prostate cancer.
    Hamel N; Kotar K; Foulkes WD
    BMC Med Genet; 2003 Aug; 4():7. PubMed ID: 12911837
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Metastatic Prostate Cancer: Effects of Genetic Testing on Care.
    Connors LM
    Clin J Oncol Nurs; 2019 Feb; 23(1):32-35. PubMed ID: 30681994
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Germline DNA Repair Gene Mutation Landscape in Chinese Prostate Cancer Patients.
    Wei Y; Wu J; Gu W; Qin X; Dai B; Lin G; Gan H; Freedland SJ; Zhu Y; Ye D
    Eur Urol; 2019 Sep; 76(3):280-283. PubMed ID: 31248605
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Germline mutations and prostate cancer: is it time to change treatment algorithms?
    Telvizian T; Mukherji D
    Chin Clin Oncol; 2020 Oct; 9(5):65. PubMed ID: 32921062
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Statewide Retrospective Review of Familial Pancreatic Cancer in Delaware, and Frequency of Genetic Mutations in Pancreatic Cancer Kindreds.
    Catts ZA; Baig MK; Milewski B; Keywan C; Guarino M; Petrelli N
    Ann Surg Oncol; 2016 May; 23(5):1729-35. PubMed ID: 26727920
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Germline Sequencing DNA Repair Genes in 5545 Men With Aggressive and Nonaggressive Prostate Cancer.
    Darst BF; Dadaev T; Saunders E; Sheng X; Wan P; Pooler L; Xia LY; Chanock S; Berndt SI; Gapstur SM; Stevens V; Albanes D; Weinstein SJ; Gnanapragasam V; Giles GG; Nguyen-Dumont T; Milne RL; Pomerantz M; Schmidt JA; Mucci L; Catalona WJ; Hetrick KN; Doheny KF; MacInnis RJ; Southey MC; Eeles RA; Wiklund F; Kote-Jarai Z; Conti DV; Haiman CA
    J Natl Cancer Inst; 2021 May; 113(5):616-625. PubMed ID: 32853339
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rare Germline Pathogenic Mutations of DNA Repair Genes Are Most Strongly Associated with Grade Group 5 Prostate Cancer.
    Wu Y; Yu H; Li S; Wiley K; Zheng SL; LaDuca H; Gielzak M; Na R; Sarver BAJ; Helfand BT; Walsh PC; Lotan TL; Cooney KA; Black MH; Xu J; Isaacs WB
    Eur Urol Oncol; 2020 Apr; 3(2):224-230. PubMed ID: 31948886
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Germline Mutations and Ancestry in Prostate Cancer.
    Bataba E; Babcock K; Isensee KA; Eldhose B; Kohaar I; Chesnut GT; Dobi A
    Curr Oncol Rep; 2024 Feb; 26(2):175-180. PubMed ID: 38265515
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Impact of germline BRCA2 and CHEK2 mutations on time to castration resistance in patients with metastatic hormone-nave prostate cancer].
    Matveev VB; Kirichek AA; Filippova MG; Savinkova AV; Khalmurzaev OA; Lyubchenko LN
    Urologiia; 2019 Dec; (5):79-85. PubMed ID: 31808637
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Germline Predisposition to Prostate Cancer in Diverse Populations.
    Bree KK; Hensley PJ; Pettaway CA
    Urol Clin North Am; 2021 Aug; 48(3):411-423. PubMed ID: 34210495
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.